These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 8625316)

  • 1. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
    Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
    Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic activation of c-fos promoter activity by Raf and Ral GDP dissociation stimulator.
    Okazaki M; Kishida S; Hinoi T; Hasegawa T; Tamada M; Kataoka T; Kikuchi A
    Oncogene; 1997 Feb; 14(5):515-21. PubMed ID: 9053849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
    Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
    Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. smg/rap1/Krev-1 p21s inhibit the signal pathway to the c-fos promoter/enhancer from c-Ki-ras p21 but not from c-raf-1 kinase in NIH3T3 cells.
    Sakoda T; Kaibuchi K; Kishi K; Kishida S; Doi K; Hoshino M; Hattori S; Takai Y
    Oncogene; 1992 Sep; 7(9):1705-11. PubMed ID: 1323817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
    Bustelo XR; Suen KL; Leftheris K; Meyers CA; Barbacid M
    Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SCH 51344 inhibits ras transformation by a novel mechanism.
    Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A
    Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
    Du J; Jiang B; Coffey RJ; Barnard J
    Mol Cancer Res; 2004 Apr; 2(4):233-41. PubMed ID: 15140945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming and c-fos promoter/enhancer-stimulating activities of a GDP/GTP exchange protein for small GTP-binding proteins.
    Takai Y; Kaibuchi K; Kikuchi A; Kawata M; Sasaki T; Yamamoto T
    Princess Takamatsu Symp; 1991; 22():197-204. PubMed ID: 1844241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Ral GDP dissociation stimulator-like (RGL) activities to regulate c-fos promoter and the GDP/GTP exchange of Ral.
    Murai H; Ikeda M; Kishida S; Ishida O; Okazaki-Kishida M; Matsuura Y; Kikuchi A
    J Biol Chem; 1997 Apr; 272(16):10483-90. PubMed ID: 9099691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
    Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ral and Rho-dependent activation of phospholipase D in v-Raf-transformed cells.
    Frankel P; Ramos M; Flom J; Bychenok S; Joseph T; Kerkhoff E; Rapp UR; Feig LA; Foster DA
    Biochem Biophys Res Commun; 1999 Feb; 255(2):502-7. PubMed ID: 10049738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between Ras and Raf: key regulatory proteins in cellular transformation.
    Marshall M
    Mol Reprod Dev; 1995 Dec; 42(4):493-9. PubMed ID: 8607981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. H-ras and raf-1 cooperate in transformation of NIH3T3 fibroblasts.
    Cuadrado A; Bruder JT; Heidaran MA; App H; Rapp UR; Aaronson SA
    Oncogene; 1993 Sep; 8(9):2443-8. PubMed ID: 8361757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Saccharomyces cerevisiae gene product SDC25 C-domain functions as an oncoprotein in NIH3T3 cells.
    Barlat I; Schweighoffer F; Chevallier-Multon MC; Duchesne M; Fath I; Landais D; Jacquet M; Tocque B
    Oncogene; 1993 Jan; 8(1):215-8. PubMed ID: 7999142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD.
    Sonoda H; Nishida K; Yoshioka T; Ohtani M; Sugita K
    Oncogene; 1996 Jul; 13(1):143-9. PubMed ID: 8700540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of the p72-74 RAF-1 kinase in 3T3 fibroblasts expressing ras or src oncogenes.
    Reed JC; Yum S; Cuddy MP; Turner BC; Rapp UR
    Cell Growth Differ; 1991 May; 2(5):235-43. PubMed ID: 1888699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergism between two growth regulatory pathways: cooperative transformation of NIH3T3 cells by G alpha 12 and c-raf-1.
    Zhang Y; Saez R; Leal MA; Chan AM
    Oncogene; 1996 Jun; 12(11):2377-83. PubMed ID: 8649778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raf revertant cells resist transformation by non-nuclear oncogenes and are deficient in the induction of early response genes by TPA and serum.
    Kolch W; Heidecker G; Troppmair J; Yanagihara K; Bassin RH; Rapp UR
    Oncogene; 1993 Feb; 8(2):361-70. PubMed ID: 8426742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-mutant analysis of the interaction of Ras with the Ras-binding domain of RGL.
    Shirouzu M; Hashimoto K; Kikuchi A; Yokoyama S
    Biochemistry; 1999 Apr; 38(16):5103-10. PubMed ID: 10213614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.